Christie Romer: The Only Surefire Way for Policymakers to Substantially Increase Aggregate Demand in the Short Run Is for the Government to Spend More and Tax Less
"Introduction to Macroeconomics": Files for August 30, 2010 U.C. Berkeley Principles of Economics Lecture, J. Bradford DeLong

In Which I Correct an Error in My "Bring Your Genes to Cal" Post of 8/29/2010…

Dean Mark Schissel makes me smarter by emailing to say that I am working off of wrong and out-of-date information. It looks as though at least one of my fears is groundless: insurance companies are not likely take genetic information about folic acid metabolism and use it to deny coverage because women with the genetic marker are more likely to have babies with neural tube defects like spina bifida. The apparent association found appears to be a “false positive”:

[Because] the MTHFR variant... has an allele frequency of ~40%... many studies have shown a correlation with this marker of some disease with a p-value of <.05, the usual cut-off for significance…. [I]f you test 100 diseases or conditions, you'll expect to get 5 false positives.... In the case of neural tube defects, there was a LOT of research on the role of MTHFR since it would have been an easily treatable cause of a serious problem. Unfortunately, the association turned out NOT to be causal...

It is disappointing to learn that the interaction of low folic acid intake with the MTHFR variant does not look to be a likely cause of neural tube defects in newborns.

It would, as Mark said, have been a very easy to treat (and very cheap to treat) cause of what is a serious medical problem.